Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on August 4, 2023, covering events occurring on August 2, 2023. The filing details the formalization of an employment agreement with Daniel Paterson, who was appointed President and Chief Executive Officer effective August 1, 2023.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Compensation
The Company entered into an indefinite-term employment agreement with CEO Daniel Paterson. Key compensation terms include:
- Base Salary: $600,000 annually.
- Annual Bonus: Target of 55% of base salary, pro-rated for the remainder of 2023.
- Equity Grants (August 2, 2023):
- 100,000 stock options at an exercise price of $10.44 per share.
- 50,000 time-based restricted stock units (RSUs).
- 50,000 performance-based RSUs tied to the FDA acceptance and approval of a New Drug Application for a product containing avutometinib in combination with defactinib.
- Vesting Schedule: Time-based equity vests 25% on the first anniversary, followed by 6.25% quarterly thereafter. Performance-based RSUs vest 50% upon FDA acceptance and 50% upon approval.
Severance and Change of Control Provisions
The agreement outlines specific severance benefits upon termination without Cause or for Good Reason:
- Standard Termination: 12 months of base salary, 12 months of COBRA premium payments, pro-rata bonus, and accelerated vesting of time-based equity that would have vested in the following 12 months.
- Change of Control Termination: If termination occurs within 90 days prior to or 18 months following a Change of Control, benefits increase to 18 months of base salary, 18 months of COBRA payments, pro-rata bonus, and full accelerated vesting of all time-based equity. Performance-based equity vests to the extent not assumed by the acquirer.
Investor Verification Checklist
- Verify the exact vesting conditions and performance milestones for the 50,000 performance-based RSUs granted to the CEO.
- Review the full text of the Employment Agreement (Exhibit 10.1) for definitions of "Cause" and "Good Reason."
- Confirm the current status of the New Drug Application for avutometinib and defactinib to assess the likelihood of performance-based vesting.
- Monitor future filings for any additional equity grants or changes to the executive compensation structure.